{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:58:00Z","timestamp":1792454280423,"version":"4.5.0"},"reference-count":138,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Cardiovascular, renal, and metabolic diseases are pathophysiologically interdependent, posing a significant global health challenge and being associated with a substantial increase in morbidity and mortality. In 2023, the American Heart Association (AHA) defined this complex network of interconnected health conditions as the cardiovascular\u2013kidney\u2013metabolic (CKM) syndrome. This syndrome is based on common pathophysiological mechanisms, including chronic inflammation, oxidative stress, hyperglycemia and insulin resistance, activation of the renin\u2013angiotensin\u2013aldosterone system (RAAS), and neurohormonal dysfunction, which trigger a vicious cycle where the impairment of one organ contributes to the progressive deterioration of the others. An integrated approach to these conditions, rather than treating them as separate entities, supports a holistic management strategy that helps to reduce the burden on public health and improve patients\u2019 quality of life. Existing management focuses on lifestyle modification, glycemic and lipid control, and the use of nephroprotective and cardioprotective therapies. This narrative review aims to synthesize and contextualize existing information on the complex interactions between these systems and on diagnostic approaches, as well as to provide an overview of the available therapeutic options.<\/jats:p>","DOI":"10.3390\/jcm14082833","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T20:24:16Z","timestamp":1745180656000},"page":"2833","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Cardiovascular\u2013Kidney\u2013Metabolic Syndrome: A New Paradigm in Clinical Medicine or Going Back to Basics?"],"prefix":"10.3390","volume":"14","author":[{"given":"Victoria","family":"Mutruc","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bologa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1721-2360","authenticated-orcid":false,"given":"Victori\u021ba","family":"\u0218orodoc","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0043-9051","authenticated-orcid":false,"given":"Alexandr","family":"Ceasovschih","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Codrina","family":"Mor\u0103ra\u0219u","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren\u021biu","family":"\u0218orodoc","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana Elena","family":"Catar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Centre Hospitalier Universitaire d\u2019Angers, 49 933 Angers, Cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0525-0645","authenticated-orcid":false,"given":"C\u0103t\u0103lina","family":"Lionte","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Second Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Nikolaou, M., Theodorakis, N., Feretzakis, G., Vamvakou, G., Hitas, C., Kalantzi, S., Spyridaki, A., Apostolos, A., Verykios, V.S., and Toutouzas, K. (2024). Nationwide Mortality Trends from 2001 to 2020 in Greece: Health Policy Implications under the Scope of Aging Societies. Hell. J. Cardiol., 28.","DOI":"10.2139\/ssrn.4713286"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jamacardio.2023.3241","article-title":"Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 1999\u20132020","volume":"8","author":"Ostrominski","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Alemany, M. (2024). The Metabolic Syndrome, a Human Disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042251"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Stefanska, K., and Sattar, N. (2025). Incretin-based weight loss therapies and heart failure with preserved ejection fraction: Guideline impactful results, but mechanisms unclear. Cardiovasc. Res., advance online publication.","DOI":"10.1093\/cvr\/cvaf001"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart Failure with Preserved Ejection Fraction: JACC Scientific Statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.2215\/CJN.02180311","article-title":"Metabolic syndrome and kidney disease: A systematic review and meta-analysis","volume":"6","author":"Thomas","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"ref_11","unstructured":"Chertow, G.M. (2023, January 3). Tackling the Triple Threat: The American Heart Association\u2019s Cardiovascular-Kidney-Metabolic Health Initiative. Presented at the American Society of Nephrology (ASN) Kidney Week 2023, Philadelphia, PA, USA."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/eurheartj\/ehae775","article-title":"From cardiorenal to cardiovascular-kidney-metabolic syndromes","volume":"46","author":"Braunwald","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and Diagnostic Criteria of Clinical Obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and cardiovascular disease: An ESC clinical consensus statement","volume":"45","author":"Koskinas","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_15","unstructured":"World Obesity Federation (2025). World Obesity Atlas 2025, World Obesity Federation."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health Effects of Overweight and Obesity in 195 Countries over 25 Years","volume":"377","author":"Afshin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","unstructured":"GBD 2021 Diabetes Collaborators (2023). Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet, 40, 203\u2013234."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"110945","DOI":"10.1016\/j.diabres.2023.110945","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"204","author":"Sun","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"The Emerging Risk Factors Collaboration (2010). Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet, 375, 2215\u20132222.","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","article-title":"CAPTURE: A multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries","volume":"20","author":"Mosenzon","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rando, M.M., Guthoff, M., Tiwari, V., and Biscetti, F. (2022). Editorial: Diagnosis, prevention and treatment in diabetic nephropathy. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1011665"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ruiz-Garc\u00eda, A., Serrano-Cumplido, A., Escobar-Cervantes, C., Arranz-Mart\u00ednez, E., Tur\u00e9gano-Yedro, M., and Pallar\u00e9s-Carratal\u00e1, V. (2023). Heart Failure Prevalence Rates and Its Association with Other Cardiovascular Diseases and Chronic Kidney Disease: SIMETAP-HF Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12154924"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Szlagor, M., Dybiec, J., M\u0142ynarska, E., Rysz, J., and Franczyk, B. (2023). Chronic Kidney Disease as a Comorbidity in Heart Failure. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032988"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"111926","DOI":"10.1016\/j.diabres.2024.111926","article-title":"Increased prevalence of cardiovascular-kidney-metabolic syndrome during COVID-19: A propensity score-matched study","volume":"218","author":"Trimarco","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/ATVBAHA.124.321629","article-title":"Sex Differences in Cardiovascular-Kidney-Metabolic Syndrome: 30-Year US Trends and Mortality Risks\u2014Brief Report","volume":"45","author":"Ji","year":"2025","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.ekir.2024.05.033","article-title":"Combination of Cardiovascular, Kidney, and Metabolic Diseases in a Syndrome Named Cardiovascular-Kidney-Metabolic, With New Risk Prediction Equations","volume":"9","author":"Massy","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/dc19-0532","article-title":"Racial\/ethnic disparities in the prevalence of diabetes and prediabetes by BMI: Patient outcomes research to advance learning (PORTAL) multisite cohort of adults in the U.S","volume":"42","author":"Zhu","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Carpenter, C., Yan, E., Chen, S., Hong, K., Arechiga, A., Kim, W.S., Deng, M., Li, Z., and Heber, D. (2013). Body fat and body-mass index among a multiethnic sample of college-age men and women. J. Obes., 790654.","DOI":"10.1155\/2013\/790654"},{"key":"ref_32","first-page":"258","article-title":"Social determinants of health and diabetes: A scientific review","volume":"44","author":"Adler","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCRESAHA.121.319811","article-title":"Social determinants of cardiovascular disease","volume":"130","author":"Baumer","year":"2022","journal-title":"Circ. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41574-019-0219-1","article-title":"From conception to infancy: Early risk factors for childhood obesity","volume":"15","author":"Larque","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/endocrines5020011","article-title":"Mechanisms of Insulin Resistance in Patients with Obesity","volume":"5","author":"Arneth","year":"2024","journal-title":"Endocrines"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/nu5041218","article-title":"Dyslipidemia in Obesity: Mechanisms and Potential Targets","volume":"5","author":"Klop","year":"2013","journal-title":"Nutrients"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"El Meouchy, P., Wahoud, M., Allam, S., Chedid, R., Karam, W., and Karam, S. (2022). Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012305"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kreiner, F., Schytz, P., Heerspink, H., and Idorn, T. (2023). Obesity-related kidney disease: Current understanding and future perspectives. Biomedicines, 11.","DOI":"10.3390\/biomedicines11092498"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Costantino, V.V., Gil Lorenzo, A.F., Bocanegra, V., and Vall\u00e9s, P.G. (2021). Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70. Cells, 10.","DOI":"10.3390\/cells10113146"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Jha, R., Lopez-Trevino, S., Kankanamalage, H.R., and Jha, J.C. (2024). Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions. Biomedicines, 12.","DOI":"10.3390\/biomedicines12051098"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrneph.2013.250","article-title":"Cardiorenal syndrome\u2014Current understanding and future perspectives","volume":"10","author":"Braam","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid Receptor and Cardiovascular Disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am. J. Hypertens."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: Pathophysiological basis","volume":"96","author":"Girerd","year":"2019","journal-title":"Kidney Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/ajh\/hpy158","article-title":"Vascular mineralocorticoid receptor: Evolutionary mediator of wound healing turned harmful by our modern lifestyle","volume":"32","author":"Biwer","year":"2019","journal-title":"Am. J. Hypertens."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Xanthopoulos, A., Papamichail, A., Briasoulis, A., Loritis, K., Bourazana, A., Magouliotis, D.E., Sarafidis, P., Stefanidis, I., Skoularigis, J., and Triposkiadis, F. (2023). Heart Failure in Patients with Chronic Kidney Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12186105"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"El Chamieh, C., Liabeuf, S., and Massy, Z. (2022). Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings. Toxins, 14.","DOI":"10.3390\/toxins14040280"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Guldan, M., Unlu, S., Abdel-Rahman, S.M., Ozbek, L., Gaipov, A., Covic, A., Soler, M.J., Covic, A., and Kanbay, M. (2024). Understanding the Role of Sex Hormones in Cardiovascular Kidney Metabolic Syndrome: Toward Personalized Therapeutic Approaches. J. Clin. Med., 13.","DOI":"10.3390\/jcm13154354"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: A clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1161\/CIRCRESAHA.121.318093","article-title":"Obesity, adipose tissue and vascular dysfunction","volume":"128","author":"Koenen","year":"2021","journal-title":"Circ Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/ijo.2010.152","article-title":"Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index","volume":"35","author":"Palaniappan","year":"2011","journal-title":"Int. J. Obes."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jacc.2021.05.035","article-title":"Management of obesity in cardiovascular practice: JACC focus seminar","volume":"78","author":"Despres","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Longo, M., Zatterale, F., Naderi, J., Parrillo, L., Formisano, P., Raciti, G.A., Beguinot, F., and Miele, C. (2019). Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092358"},{"key":"ref_55","first-page":"e984","article-title":"Obesity and cardiovascular disease: A scientific statement from the American Heart Association","volume":"143","author":"Poirier","year":"2021","journal-title":"Circulation"},{"key":"ref_56","unstructured":"World Health Organization (2019). Classification of Diabetes Mellitus."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2025). 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes\u20142025. Diabetes Care, 48, S27\u2013S49.","DOI":"10.2337\/dc25-S002"},{"key":"ref_58","unstructured":"(2024). Kidney Disease: Improving Global Outcomes CKD Work Group KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int., 3, S117\u2013S314."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wu, X., Hu, W., Xu, J., Shen, J., Lin, L., Zhu, J., Wei, T., and Lv, L. (2025). Difference between estimated glomerular filtration rate based on cystatin C versus creatinine and cardiovascular\u2013kidney\u2013metabolic health. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1477343"},{"key":"ref_60","first-page":"e895","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jchf.2022.12.005","article-title":"Reclassification of pre-heart failure stages using cardiac biomarkers: Atherosclerosis Risk in Communities (ARIC) study","volume":"11","author":"Jia","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) With the Special Contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pcad.2024.10.012","article-title":"Cardiovascular-kidney-metabolic syndrome\u2014An integrative review","volume":"87","author":"Kittelson","year":"2024","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejim.2023.12.006","article-title":"Elevated cardiac biomarkers in relatively healthy U.S. adults","volume":"121","author":"Claudel","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.cmet.2023.10.015","article-title":"Cardiovascular-kidney-metabolic syndrome: A step toward multidisciplinary and inclusive care","volume":"35","author":"Claudel","year":"2023","journal-title":"Cell Metab."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Lanlan, W., and Zheng, H. (2024). Elevated triglyceride glucose index is associated with advanced cardiovascular kidney metabolic syndrome. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-82881-y"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12933-025-02662-3","article-title":"Comparison of triglyceride glucose index and modified triglyceride glucose indices in predicting cardiovascular diseases incidence among populations with cardiovascular-kidney-metabolic syndrome stages 0\u20133: A nationwide prospective cohort study","volume":"24","author":"Hong","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Li, Y.-W., Kao, T.-W., Chang, P.-K., Chen, W.-L., and Wu, L.-W. (2021). Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: A 9-year longitudinal study. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-89307-z"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12933-023-01740-8","article-title":"Sex-specific differences in the effect of the atherogenic index of plasma on prediabetes and diabetes in the NHANES 2011\u20132018 population","volume":"22","author":"Shi","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12944-018-0932-0","article-title":"Atherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease in obese participants: A cross-sectional study","volume":"17","author":"Wang","year":"2018","journal-title":"Lipids Health Dis."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Song, Y., Lu, Y., Liu, T., and Yin, P. (2025). Atherogenic index of plasma and cardiovascular disease risk in cardiovascular-kidney-metabolic syndrome stage 1 to 3: A longitudinal study. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1517658"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A Consensus Statement of the European Atherosclerosis Society","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14779072.2021.2021071","article-title":"Serum uric acid: A mediator of cardio-reno-metabolic diseases","volume":"19","author":"Katsiki","year":"2021","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40292-023-00602-4","article-title":"The results of the URRAH (Uric Acid Right for Heart Health) project: A focus on hyperuricemia in relation to cardiovascular and kidney disease and its role in metabolic dysregulation","volume":"30","author":"Maloberti","year":"2023","journal-title":"High Blood Press. Cardiovasc. Prevent."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Gao, C., Gao, S., Zhao, R., Shen, P., Zhu, X., Yang, Y., Duan, C., Wang, Y., Ni, H., and Zhou, L. (2024). Association between systemic immune-inflammation index and cardiovascular-kidney-metabolic syndrome. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-69819-0"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Cao, Y., Wang, W., Xie, S., Xu, Y., and Lin, Z. (2025). Joint association of the inflammatory marker and cardiovascular-kidney-metabolic syndrome stages with all-cause and cardiovascular disease mortality: A national prospective study. BMC Public Health, 25.","DOI":"10.1186\/s12889-024-21131-2"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e33366","DOI":"10.1097\/MD.0000000000033366","article-title":"Management of diabetic kidney disease: Where do we stand?: A narrative review","volume":"102","author":"Sindhu","year":"2023","journal-title":"Medicine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.2337\/dc24-S011","article-title":"Chronic kidney disease and risk management: Standards of care in diabetes","volume":"47","author":"ElSayed","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/CIRCULATIONAHA.124.071079","article-title":"Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review","volume":"151","author":"Claudel","year":"2025","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_83","unstructured":"Gaggin, H.K., and Januzzi, J.L. (2025, March 11). Update. Cardiac Biomarkers and Heart Failure. Expert analysis. 5 May 2023. Available online: https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2015\/02\/09\/13\/00\/Cardiac-Biomarkers-and-Heart-Failure."},{"key":"ref_84","first-page":"53445","article-title":"Novel Biomarkers in Early Detection of Heart Failure: A Narrative Review","volume":"16","author":"Kayani","year":"2024","journal-title":"Cureus"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/eurheartjsupp\/suae100","article-title":"Cardiovascular Risk Assessment in Daily Clinical Practice: When and How to Use a Risk Score","volume":"27","author":"Panattoni","year":"2025","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"SCORE2-OP working Group and ESC Cardiovascular Risk Collaboration (2021). SCORE2-OP risk prediction algorithms: Estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur. Heart J., 42, 2455\u20132467.","DOI":"10.1093\/eurheartj\/ehab312"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration (2023). SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur. Heart J., 44, 2544\u20132556.","DOI":"10.1093\/eurheartj\/ehad260"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/eurjpc\/zwac176","article-title":"Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP","volume":"30","author":"Matsushita","year":"2023","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"SCORE2 Asia-Pacific Writing Group, Hageman, S.H.J., Huang, Z., Lee, H., Kaptoge, S., Dorresteijn, J.A.N., Pennells, L., Di Angelantonio, E., Visseren, F.L.J., and Kim, H.C. (2025). Risk prediction of cardiovascular disease in the Asia-Pacific region: The SCORE2 Asia-Pacific model. Eur. Heart J., 46, 702\u2013715.","DOI":"10.1093\/eurheartj\/ehae609"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association","volume":"48","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/eurjpc\/zwae174","article-title":"Prediction of individual lifetime cardiovascular risk and potential treatment benefit: Development and recalibration of the LIFE-CVD2 model to four European risk regions","volume":"31","author":"Hageman","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e002262","DOI":"10.1161\/CIRCIMAGING.114.002262","article-title":"Comparison of coronary artery calcium presence, carotid plaque presence, and carotid intima-media thickness for cardiovascular disease prediction in the Multi-Ethnic Study of Atherosclerosis","volume":"8","author":"Gepner","year":"2015","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2010.461","article-title":"Coronary artery calcium score and risk classification for coronary heart disease prediction","volume":"303","author":"Polonsky","year":"2010","journal-title":"JAMA"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Emberson, M.A., Lalande, A., Wang, D., McDonough, D.J., Liu, W., and Gao, Z. (2021). Effectiveness of smartphone-based physical activity interventions on individuals\u2019 health outcomes: A systematic review. Biomed. Res. Int.","DOI":"10.1155\/2021\/6296896"},{"key":"ref_95","first-page":"e18","article-title":"Life\u2019s essential 8: Updating and enhancing the American Heart Association\u2019s construct of cardiovascular health: A presidential advisory from the American Heart Association","volume":"146","author":"Allen","year":"2022","journal-title":"Circulation"},{"key":"ref_96","first-page":"15","article-title":"A Review of Current Guidelines for the Treatment of Obesity","volume":"28","year":"2022","journal-title":"Am. J. Manag. Care"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr. Pract."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63 Part B","author":"Jensen","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Astrup","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of Liraglutide for Weight Loss Among Patients with Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"McGuire, D.K., Marx, N., Mulvagh, S.L., Deanfield, J.E., Inzucchi, S.E., Pop-Busui, R., Mann, J.F.E., Emerson, S.S., Poulter, N.R., and Engelmann, M.D.M. (2025). Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N. Engl. J. Med, advance online publication.","DOI":"10.1056\/NEJMoa2501006"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Bonaca, M.P., Catarig, A.-M., Houlind, K., Ludvik, B., Nordanstig, J., Ramesh, C.K., Rasouli, N., Sourij, H., Videmark, A., and Verma, S. (2025). Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): A phase 3b, double-blind, randomised, placebo-controlled trial. Lancet, advance online publication.","DOI":"10.1016\/S0140-6736(25)00509-4"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_110","first-page":"1445","article-title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","volume":"394","author":"Jastreboff","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Packer, M., Zile, M.R., Kramer, C.M., Murakami, M., Ou, Y., and Borlaug, B.A. (2025). Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients with Heart Failure, Preserved Ejection Fraction, and Obesity The SUMMIT Trial. J. Am. Coll. Cardiol., advance online publication.","DOI":"10.1016\/j.jacc.2025.03.009"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Rationale and Design of the DELIVER Trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J.R., Preiss, D., Judge, P., and Mayne, K.J. (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"FINEARTS-HF Committees and Investigators. Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"39","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/MCG.0000000000001916","article-title":"Summarizing Consensus Guidelines on Obesity Management","volume":"57","author":"Sharaiha","year":"2023","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/s41440-024-01723-6","article-title":"The Relationship Between SGLT2 and Systemic Blood Pressure Regulation","volume":"47","author":"Ahwin","year":"2024","journal-title":"Hypertens. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/heartjnl-2024-324170","article-title":"Tirzepatide and Blood Pressure Reduction: Stratified Analyses of the SURMOUNT-1 Randomised Controlled Trial","volume":"110","author":"Krumholz","year":"2024","journal-title":"Heart"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2025). 6. Glycemic goals and hypoglycemia: Standards of Care in Diabetes\u20142025. Diabetes Care, 48, S128\u2013S145.","DOI":"10.2337\/dc25-S006"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: A Meta-Analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"155931","DOI":"10.1016\/j.metabol.2024.155931","article-title":"DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","volume":"159","author":"Handelsman","year":"2024","journal-title":"Metabolism"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity\u2014A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2024.07.014","article-title":"Exploring the nexus: The place of kidney diseases within the cardiovascular-kidney-metabolic syndrome spectrum","volume":"127","author":"Kanbay","year":"2024","journal-title":"Eur. J. Int. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcmg.2022.06.018","article-title":"Major Global Coronary Artery Calcium Guidelines","volume":"16","author":"Golub","year":"2023","journal-title":"J. Am. Coll. Cardiol. Imaging"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_134","unstructured":"Nuffield Department of Population Health Renal Studies Group, and SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (2022). Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet, 400, 1788\u20131801."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure with Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"83","author":"Maddox","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2833\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:18:02Z","timestamp":1760030282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":138,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14082833"],"URL":"https:\/\/doi.org\/10.3390\/jcm14082833","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]}}}